Medicine and Dentistry
Endometrial Cancer
100%
Gynecological Oncology
80%
Neoplasm
62%
Disease
61%
Cervical Cancer
60%
Endometrium Carcinoma
49%
Ovarian Cancer
39%
Recurrent Disease
36%
Radiation Therapy
33%
Oncology
33%
Overall Survival
32%
Progression Free Survival
24%
Phase II Trials
24%
Krukenberg Tumor
23%
Adenocarcinoma
21%
Malignant Neoplasm
21%
Topotecan
21%
Pelvis
20%
Gestational Trophoblastic Disease
20%
Cancer Recurrence
19%
Cisplatin
19%
Metastatic Carcinoma
18%
Cervix
16%
Lenvatinib
16%
Adjuvant Therapy
15%
Carcinosarcoma
15%
Clinical Trial
14%
Cancer
14%
Paclitaxel
13%
Retroperitoneal Lymph Node Dissection
13%
Pemetrexed
13%
Pembrolizumab
13%
Prognostic Factor
12%
Arm
12%
Doxorubicin
12%
Primary Tumor
10%
Brachytherapy
10%
Squamous Cell Carcinoma
10%
Hazard Ratio
10%
Recurrence Risk
10%
Gemcitabine
9%
Hormone Therapy
9%
Uterine Cancer
9%
Female Genital Tract Cancer
9%
Adverse Event
9%
Lymph Node Metastasis
9%
Paraaortic Lymph Node
9%
Endometrium
8%
Protein P53
8%
Biological Marker
8%
Pharmacology, Toxicology and Pharmaceutical Science
Endometrium Cancer
60%
Chemotherapy
48%
Cisplatin
34%
Endometrium Carcinoma
32%
Disease
32%
Overall Survival
29%
Paclitaxel
27%
Uterine Cervix Cancer
26%
Neoplasm
26%
Progression Free Survival
24%
Phase II Trials
24%
Ovary Cancer
19%
Recurrent Disease
19%
Topotecan
17%
Trophoblastic Tumor
17%
Doxorubicin
17%
Carboplatin
17%
Malignant Neoplasm
15%
Adverse Event
14%
Squamous Cell Carcinoma
13%
Pembrolizumab
13%
Ovary Carcinoma
13%
Lenvatinib
13%
Clinical Trial
12%
Protein P53
11%
Cancer Recurrence
11%
Methotrexate
11%
Carcinoma
10%
Pemetrexed
9%
Gemcitabine
9%
Adenoviridae
9%
Taxane
9%
Adenocarcinoma
9%
Recurrence Free Survival
8%
Female Genital Tract Cancer
7%
Neutropenia
7%
Chemoradiation Therapy
7%
Hypothalamic Amenorrhea
6%
Dactinomycin
6%
Remission
6%
Selinexor
6%
Hormone Cancer Therapy
6%
Hydatidiform Mole
6%
Placebo
5%
Recurrence Risk
5%
Leukopenia
5%
Keyphrases
Gynecologic Oncology Group
37%
NRG Oncology
29%
Phase II Trial
28%
Endometrial Cancer
27%
Group Studies
26%
Overall Survival
21%
Chemotherapy
20%
Endometrial Carcinoma
18%
Ovarian Cancer
17%
Recurrent Endometrial Cancer
17%
Cisplatin
14%
Tumor
13%
Topotecan
13%
Hazard Ratio
13%
Radiation Therapy
12%
Invasive Cervical Cancer
11%
Confidence Interval
11%
Histology
11%
Uterine Leiomyosarcoma
9%
Adjuvant Therapy
9%
Randomized Phase III Trial
9%
Gynecological Cancer
8%
Doxorubicin
8%
Cervical Cancer
8%
Paclitaxel
8%
Progression-free Survival
7%
Epithelial Ovarian Carcinoma
7%
Adenocarcinoma
7%
Endometrioid Endometrial Cancer
7%
Cancer Patients
7%
Gynecologic Oncology
7%
ENGOT
7%
Recurrence Risk
6%
Carcinoma in Situ
6%
Pemetrexed
6%
LY231514
6%
Cervical Cancer Recurrence
6%
Hypothalamic Amenorrhea
6%
Gemcitabine
6%
Carboplatin-paclitaxel
6%
Malignant Disease
6%
Low Malignant Potential Tumor
6%
Locally Advanced
6%
Oncology Studies
6%
Placental Site Trophoblastic Tumor
6%
Uterine Corpus
6%
Critical Reassessments
6%
Lenvatinib
6%
Low-risk Gestational Trophoblastic Neoplasia
6%
Selinexor
6%